Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Revenue (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Revenue data on record, last reported at $6740.0 in Q3 2025.

  • For Q3 2025, Revenue fell 99.7% year-over-year to $6740.0; the TTM value through Sep 2025 reached -$1.1 million, down 103.96%, while the annual FY2024 figure was $10.0 million, 60.28% down from the prior year.
  • Revenue reached $6740.0 in Q3 2025 per CAPR's latest filing, down from $12485.0 in the prior quarter.
  • Across five years, Revenue topped out at $12.1 million in Q4 2023 and bottomed at -$1.1 million in Q4 2024.
  • Average Revenue over 5 years is $2.9 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Revenue: surged 1955.53% in 2023, then tumbled 109.43% in 2024.
  • A 5-year view of Revenue shows it stood at $204082.0 in 2021, then surged by 370.35% to $959903.0 in 2022, then skyrocketed by 1159.3% to $12.1 million in 2023, then crashed by 109.43% to -$1.1 million in 2024, then skyrocketed by 100.59% to $6740.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $6740.0 in Q3 2025, $12485.0 in Q1 2025, and -$1.1 million in Q4 2024.